

# Methylphenidate sustained released OROS formulation (Concerta XL™)

(No. 04/02)

Janssen-Cilag

---

## Summary of Recommendation

5 July 2002

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

### **ADVICE**

Recommended for restricted use within the NHS in Scotland.

### **REASONS FOR ADVICE**

Treatment with methylphenidate should be part of a comprehensive treatment programme for attention-deficit hyperactivity disorder (ADHD) when remedial measures alone prove insufficient (under specialist supervision). Because of its substantially greater costs, methylphenidate OROS should be restricted to second line therapy and used only in exceptional circumstances where the supervising clinician has clear evidence of compliance problems. As for other methylphenidate preparations, initiation should be on the recommendation of a specialist in childhood behaviour disorders.

Professor David H Lawson  
Chairman